Forest’s Board Grows, As Icahn Gains Second Director’s Seat
This article was originally published in The Pink Sheet Daily
Executive Summary
Dissident shareholder Carl Icahn will have some influence on the succession process as the New York drugmaker seeks a replacement for its retiring octogenarian CEO. Forest still needs to compensate for the loss of blockbuster antidepressant Lexapro, and could consider a sale or dramatic restructuring.